Login to Your Account

Clinic Roundup

Friday, October 14, 2011
Telik Inc., of Palo Alto, Calif., initiated a Phase IIb trial evaluating Telintra (ezatiostat HCl) in patients with low to intermediate-1 IPSS risk, transfusion-dependent, nondeletion myelodysplastic syndrome, who have not been treated with hypomethylating agents such as Vidaza or Dacogen.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription